bioRxivCancer Biology
The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes
A. K. Riley, M. Grant, A. Snell, A. Vichas, S. Moorthi, A. Urisman, P. Castel, L. Wan, A. Berger
Abstract
RIT1 is a rare and understudied oncogene in lung cancer. Despite structural similarity to other RAS GTPase proteins such as KRAS, oncogenic RIT1 activity does not appear to be tightly regulated by nucleotide exchange or hydrolysis. Instead, there is a growing understanding that the protein abundance of RIT1 is important for its regulation and function. We previously identified the deubiquitinase USP9X as a RIT1 dependency in RIT1-mutant cells. Here, we demonstrate that both wild-type and mutant forms of RIT1 are substrates of USP9X. Depletion of USP9X leads to decreased RIT1 protein stability and abundance and resensitizes cells to EGFR tyrosine kinase inhibitors. Our work expands upon the current understanding of RIT1 protein regulation and presents USP9X as a key regulator of RIT1-driven oncogenic phenotypes.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mapping the unique and shared functions of oncogenic KRAS and RIT1 with proteome and transcriptome profiling
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer
Athea Vichas, Naomi T. Nkinsi, … Alice H. Berger·bioRxiv·Jul 3, 2020
- Global analysis of cancer cell responses to USP9X inhibition
Philipp Schenk, Shane M. Devine, … David Komander·The EMBO JournalPeer-reviewed·Apr 7, 2026
- Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state
Mary C. Rominger, Siobhan O’Brien, … Alice H. Berger·Cell ReportsPeer-reviewed·Sep 25, 2025
- Increased dosage of wild-type KRAS protein drives KRAS-mutant lung tumorigenesis and drug resistance
T. Ivanisevic, W. Magits, … A. Sablina·bioRxiv·Feb 27, 2024
- USP28 enables oncogenic transformation of respiratory cells and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.
C. Prieto-Garcia, O. Hartmann, … M. E. Diefenbacher·bioRxiv·Sep 6, 2021